OCALIVA Efficacy: Clinical Guidance

OCALIVA Is Recommended in the Most Recent Clinical Guidance From ACG and AASLD1,2

2019 ACG Expert Opinion and 2018 AASLD Guidance recommend OCALIVA be used in combination with UDCA for patients who have not achieved their treatment goal on UDCA. OCALIVA is also indicated as monotherapy for patients who cannot tolerate UDCA.1,2

Guidance for Adding Ocaliva1,2

Click each button below to explore and compare in-depth clinical guidance and expert opinion on the evaluation, treatment, and care of patients with PBC.

INITIATE UDCA

for PBC patients with abnormal liver enzyme values

EVALUATE BIOCHEMICAL RESPONSE

at 12 months, and every 3 to 6 months thereafter

CONSIDER OCALIVA

for appropriate patients who have not achieved their treatment goals

Start Patients on OCALIVA

Interconnect® Enrollment Form

Download the Enrollment Form

For help enrolling: 1-844-622-4278

For help enrolling: 1-844-622-4278

How Does OCALIVA Impact Alkaline Phosphatase and Bilirubin?

Over 1 year, OCALIVA + UDCA provided sustained reductions in alkaline phosphatase and maintained bilirubin within normal range.3,4

See the data

AASLD, American Association for the Study of Liver Diseases; ACG, American College of Gastroenterology; PBC, primary biliary cholangitis; UDCA, ursodeoxycholic acid.

OCALIVA obeticholic acid OCALIVA obeticholic acid

Enroll for updates

Get the emails you want about OCALIVA:

  • You choose the topics
  • Content is intended for US healthcare professionals

REGISTER FOR UPDATES

Register for Updates Close

*Required fields. Invalid entry. Please try again.

First name required
Last name required
Email required
Specialty Profession required


REGISTER


 

Thank you for your interest

You can expect a confirmation email shortly to set your preferences.

References:

  1. Younossi ZM, Bernstein D, Shiffman ML, et al. Diagnosis and management of primary biliary cholangitis. Am J Gastroenterol. 2019;114(1):48-63. doi: 10.1038/s41395-018-0390-3.
  2. Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69(1):394-419. doi: 10.1002/hep.30145.
  3. OCALIVA [package insert]. New York, NY: Intercept Pharmaceuticals, Inc.; 2018.
  4. Nevens F, Andreone P, Mazzella G, et al; for the POISE Study Group. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375(7):631-643.
OCALICA obeticholic acid

Enroll for updates

REGISTER FOR UPDATES

Register for Updates Close

*Required fields. Invalid entry. Please try again.

First name required
Last name required
Email required
Specialty Profession required


REGISTER


 

Thank you for your interest

You can expect a confirmation email shortly to set your preferences.

OCALIVA® (obeticholic acid)

Patient Assistance: 1-844-622-4278

This site is intended for US healthcare professionals only Home Visit Patient Site Prescribing Information Important Safety Information

Patient Assistance:
1-844-622-4278

You are about to leave Ocalivahcp.com

Click CONTINUE to go to the page you requested or click CANCEL to remain on this page.

Cancel Continue